P EO P LE
New Editorial Advisory Board members Rainer Bischoff joined the University of Groningen (The Netherlands) in 2001 after 15 years at start-up biotechs and major pharmaceutical companies. The research in his group focuses on biomarker discovery and affinity-based protein-enrichment strategies as part of an integrated proteomics system. After receiving his Ph.D. in chemistry from the University of Göttingen (Germany), Bischoff did a postdoc at Purdue University, where he developed novel affinity chromatography materials. He became acquainted with protein chemistry while working at Transgene S.A. (France) and AstraZeneca (Sweden). Joachim Klose is professor of human genetics and director of the Proteome Research Group at the Charité-University Medicine Berlin. He studied biology and medicine in Berlin and Munich and was at the State University of New York, Buffalo, for 2 years. In 1975, Klose published what was then the novel concept of studying all of the proteins in a cell. He is a founder and council member of HUPO and initiated the HUPO Brain Proteome Project. His particular interest is the regulatory network of the cellular proteome. Akhilesh Pandey is an associate professor of genetic medicine, biological chemistry, oncology, and pathology at Johns Hopkins University. He obtained his Ph.D. at the University of Michigan and completed his residency training in clinical pathology at Harvard Medical School. His research interests include the global analysis of phosphoproteins, the development of methods for quantitative analysis of proteins (stable-isotope labeling by amino
acids in cell culture, known as SILAC), and the development of the Human Protein Reference Database. Pandey is also the founder of the Institute of Bioinformatics, a nonprofit research center in India. Peipei Ping is a professor of physiology and medicine (cardiology) at the David Geffen School of Medicine at the University of California, Los Angeles. Ping heads a project on myocardial ischemic injury, which is supported by a National Heart, Lung, and Blood Institute program. She also is the director of the Core Proteomic Laboratory at the Cardiovascular Research Laboratories. Her research program focuses on the characterization of cellular pathways and organelles in the heart, with a particular interest on altered functional subproteomes during myocardial ischemic injury. Ping has served on the editorial boards of several journals, including American Journal of Physiology, Circulation Research, and Circulation. She is a Fellow of the American Physiological Society (Cardiovascular Section) and a Fellow of the American Heart Association. Ping is an active member of the HUPO Publications Committee. Michael Snyder is the Lewis B. Cullman Professor of Molecular and Cellular Biology and a professor of molecular biophysics and biochemistry at Yale University. He is also the director of the Yale Center for Genomics and Proteomics. He obtained his Ph.D. at the California Institute of Technology and received postdoctoral training at Stanford University. Snyder’s laboratory performed the first largescale functional genomics project in any organism. They also built the first proteome chip for an organism and the first high-resolution tiling array for the entire human genome. Currently, they are conducting a large-scale analysis using protein microarrays and a global mapping of the binding sites of chromosomal
proteins. Snyder is an editor of several journals, including Functional and Integrative Genomics, Molecular and Cellular Proteomics, Drug Discovery Today, PLoS Genetics, and Genes and Development. He serves on many international advisory boards and was a cofounder of Protometrix, Inc., a protein-microarray company that is now part of Invitrogen. Timothy D. Veenstra is the director of the Laboratory of Proteomics and Analytical Technologies, SAICFrederick, Inc., at the National Cancer Institute (NCI). Veenstra holds a Ph.D. in biochemistry from the University of Windsor (Canada) and completed his postdoctoral training in molecular and cellular biology at the Mayo Clinic/Foundation. Veenstra joined NCI-Frederick in the fall of 2001 to implement a state-of-the-art MS center that focuses on the discovery of signaling pathways and networks that are activated within cells as a response to external perturbations. His laboratory also is keenly interested in using highthroughput proteomic approaches for the discovery of biomarkers for diseases such as cancer. Susan T. Weintraub is a professor of biochemistry at the University of Texas Health Science Center at San Antonio and directs the institutional MS facility there. Her training includes B.S. and M.S. degrees in chemistry and a Ph.D. in biochemistry. She has been involved in MS for the analysis of biomolecules since the early 1970s, starting with the quantitative analysis of choline and acetylcholine in rat-brain regions. She focused on phospholipids for many years—in particular, PlateletActivating Factor. Now, her main emphasis is on the identification and characterization of proteins. Weintraub’s laboratory predominantly uses 2DE gels for differential expression analysis and a variety of MS approaches for protein identification and localization of sites of posttranslational modifications.
Journal of Proteome Research • Vol. 6, No. 1, 2007 23
